Study shows IL-23 inhibitors linked to lowest risk on paradoxical AD in PsO patients

According to a recent study, IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical atopic dermatitis (AD) compared to other biologics.